Dr Harriet Walter
Associate Professor of Medical Oncology and Honorary Consultant Medical Oncologist
Department: Genetics and Genome Biology, Department of
Telephone: +44 (0)116 258 7603
Email: hw191@leicester.ac.uk
Profile
Research
Publications
Publications
(0) Danilov AV, Herbaux C, Walter HS, et al. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020;26(12):2810-2818. doi:10.1158/1078-0432.CCR-19-3504.
Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstram macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112-e121. doi:10.1016/S2352-3026(19)30210-8.
Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765-2775. doi:10.1182/blood-2019-01-896290
Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019; 104(2): e68-e71.
Walter HS, Trethewey C, Matthew J. Ahearne et al. Successful treatment of primary cutaneous diffuse large B cell lymphoma leg type with single agent venetoclax. JCO Precision Oncology.
Kozaki R, Vogler M, Walter HS et al. Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers (Basel). 2018; 10(4): pii: E127.
Vogler M, Walter HS, Dyer MJS. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. Br J Haematol. 2017; 178(3): 364-379.
Walter HS, Jayne S, Rule SA et al. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017; 129(20):2808-2810.
Walter HS, Jayne S, Mensah P et al. Obinutuzumab-induced coagulopathy in chronic lymphocytic leukemia (CLL) with trisomy 12. Blood Cancer Journal (2016) 6, e435; doi:10.1038/bcj.2016.42.
Walter HS, Salles GA, Dyer MJ. New agents to treat chronic lymphocytic leukemia. N Engl J Med. 2016; 374(22): 2185-2186.
Walter HS, Rule SA, Dyer MJ et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016; 127(4): 411-9.